Grants and Contracts Details
The Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) will assess whether one of the most commonly used anti-VEGF drgus, bevacizumab, is non-inferior to a second generation anti-VEGF drug, aflibercept, for the treatment of macular edema secondary to Central Retinal Vein Occlusion. Rescue therapy, in cases where intial therapy is not successful, will be evaluated.
|Effective start/end date||9/30/13 → 3/31/19|
- The Pennsylvania State University: $19,494.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.